<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903253</url>
  </required_header>
  <id_info>
    <org_study_id>LNK754-0901-1A</org_study_id>
    <nct_id>NCT00903253</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers</brief_title>
  <official_title>A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Link Medicine Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Link Medicine Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the single-dose plasma pharmacokinetics of LNK-754&#xD;
      as well as safety and tolerability in normal healthy male and female elderly volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Elderly Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNK-754</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and Females aged 60 to 75 years&#xD;
&#xD;
          -  Good general health as determined by medical history and physical examination&#xD;
&#xD;
          -  Body Mass Index of 18-32, inclusive&#xD;
&#xD;
          -  Estimate of creatinine clearance by Cockcroft-Gault that is normal for age and sex&#xD;
             (greater than or equal to 60mL/min)&#xD;
&#xD;
          -  Normal hemoccult test at screening and baseline&#xD;
&#xD;
          -  Voluntarily consent to participate in the study&#xD;
&#xD;
          -  Willing to adhere to the protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with clinically significant cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, neurological, sleep disorders by DSM-IV criteria, endocrine,&#xD;
             hematological, or metabolic disease as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  Subjects who have been diagnosed with or meet the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders Fourth Edition, Text Revision (DSM-IV_TR) criteria for any&#xD;
             significant psychiatric or psychoactive substance use disorder within the past year&#xD;
&#xD;
          -  Subjects with positive urine drug screen or compounds associated with abuse in the&#xD;
             absence of medical justification for their presence&#xD;
&#xD;
          -  QTcB greater than 450 msec (males), or greater than 470 (females), based on the&#xD;
             average interval of triplicate ECGs obtained after five minutes rest in a supine&#xD;
             position using hte ECG algorithm&#xD;
&#xD;
          -  Clinically significant abnormal screening results or laboratory tests&#xD;
&#xD;
          -  Pregnant or nursing or planning a pregnancy, or planning on fathering a child&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CEDRA Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

